Answers are grounded in this paper and cite their sources.
Case report reveals effective and safe daratumumab treatment for renal relapse after heart and stem cell transplantation, suggesting a salvage therapy option in AL amyloidosis.
There is no recommendation on what salvage therapy is optimal in the solid organ recipient with AL amyloidosis, such as a heart transplant. With this case, we illustrate how treatment with daratumumab may be effective and safe in a patient with AL amyloidosis with renal involvement at the relapse after heart transplantation and autologous stem cell transplantation.
No takes yet. Share an insight, caveat, or question.
Puertas et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: